Zim Laboratories Limited
All news and filings related to Zim Laboratories Limited.
View all news & filings- Medium impact
Zim Laboratories Incorporates Wholly Owned Subsidiary in Chile
Zim Laboratories Limited has incorporated a wholly owned subsidiary, ZIM Laboratories SpA, in Santiago, Chile, on September 9, 2026. This expansion aims to develop its pharmaceutical business in the LATAM region. The holding company subscribed to 14,100 shares for cash consideration.
Read the summary - Low impact
Zim Laboratories FZE Completes Investment in ZIM Scientific Office LLC
Zim Laboratories Limited FZE has completed its investment in step-down subsidiary ZIM Scientific Office LLC. The full approved amount has been invested, maintaining ZIM FZE's 100% shareholding in ZIM SO. This follows previous disclosures regarding planned investments.
Read the summary - Medium impact
Zim Laboratories Q1 FY27 Earnings Call Transcript Released
Zim Laboratories reported Q1 FY27 operating income grew 31.2% YoY to ₹94.2 crore, with a net loss of ₹4 crore. Exports formed 84% of revenue. The company is awaiting EU-GMP certification, crucial for unlocking significant growth, with potential for 30-40% top-line increase in FY28. Australian TGA certification is also anticipated soon.
Read the summary - Medium impact
Zim Laboratories Limited Shareholders Approve Special Resolutions on Director Remuneration
Zim Laboratories Limited shareholders approved special resolutions concerning the remuneration of its Managing Director, Dr. Anwar Daud, and Whole-Time Director, Mr. Zulfiquar Kamal, via postal ballot. The voting concluded on August 11, 2026, with results announced on August 12, 2026.
Read the summary - Low impact
Zim Laboratories Q1 FY27 Earnings Conference Call Audio Recording Available
Zim Laboratories Limited has released the audio recording for its Q1 FY27 Earnings Conference Call. The recording is available on the company's website. This announcement complies with SEBI Listing Regulations.
Read the summary - Low impact
Zim Laboratories Publishes Financial Results for Q1 FY27
Zim Laboratories Limited announced its financial results for the quarter ended June 30, 2026. The company published the results on August 7, 2026, in compliance with SEBI regulations. The announcement was featured in the Financial Express, Indian Express, and Loksatta newspapers.
Read the summary - Medium impact
Zim Laboratories Q1 FY27 Earnings Presentation: Revenue Up 31.2% YoY to ₹94.2 Crore
Zim Laboratories reported Q1 FY27 Total Operating Income of ₹94.2 crore, up 31.2% YoY but down 10.5% QoQ. EBITDA decreased 40% YoY to ₹3.4 crore, with margins at 3.7%. PAT was a loss of ₹4 crore. Innovative product revenue grew threefold to ₹13.8 crore, contributing 15% to TOI.
Read the summary - Medium impact
Zim Labs Q1 FY27 Results: Consolidated Net Loss Widens to ₹4.02 Cr
Zim Laboratories Limited reported unaudited financial results for Q1 FY27. Consolidated revenue increased to ₹94.18 crore from ₹71.76 crore YoY. However, consolidated net loss widened to ₹4.02 crore from ₹1.87 crore. Standalone revenue grew to ₹93.05 crore from ₹71.43 crore, with a standalone net loss of ₹3.88 crore.
Read the summary - Low impact
Zim Laboratories Limited Schedules Q1FY27 Earnings Conference Call for August 7, 2026
Zim Laboratories Limited will hold its Q1FY27 Earnings Conference Call on Friday, August 7, 2026, at 12:00 PM IST. Key management, including the Director of Finance and CFO, will participate. Investors can pre-register for the call.
Read the summary - Low impact
Zim Laboratories Announces Transfer of Equity Shares to IEPF Account
Zim Laboratories Limited is transferring equity shares with unclaimed dividends for seven years to the IEPF Account. Shareholders have until October 31, 2026, to claim their dividends. The notice was published on July 30, 2026.
Read the summary - Low impact
Zim Laboratories Allots 1,09,451 Equity Shares Under ESOS 2023
Zim Laboratories Limited allotted 1,09,451 equity shares under its ESOS 2023. This allotment, approved on July 13, 2026, increased the paid-up equity share capital to ₹53,65,84,880. The company realized ₹84,71,507.40 from the exercise of these options.
Read the summary - Low impact
Zim Laboratories Submits Newspaper Publication for Postal Ballot Notice
Zim Laboratories Limited has published a Postal Ballot Notice in The Financial Express, Indian Express, and Loksatta. This is a regulatory filing as per SEBI LODR regulations.
Read the summary - Medium impact
Zim Laboratories Seeks Shareholder Approval for Director Remuneration Revision
Zim Laboratories is seeking shareholder approval via postal ballot to revise the remuneration of its Managing Director, Dr. Anwar Daud, and Whole-Time Director, Mr. Zulfiquar Kamal. The e-voting period is from July 13, 2026, to August 11, 2026, with results expected by August 13, 2026.
Read the summary - Low impact
Zim Laboratories to Meet Canara HSBC Life Insurance on July 3, 2026
Zim Laboratories Limited will conduct an in-person, one-to-one meeting with Canara HSBC Life Insurance on Friday, July 3rd, 2026. No Unpublished Price Sensitive Information will be disclosed during the meeting.
Read the summary - Low impact
Zim Laboratories to Meet Tata Asset Management on July 3, 2026
Zim Laboratories Limited will hold an in-person investor meet with Tata Asset Management Pvt. Ltd. on July 3, 2026. No unpublished price-sensitive information will be disclosed during the meeting. The schedule is subject to change.
Read the summary - Low impact
Zim Laboratories Limited: 42nd AGM Concludes Successfully on June 29, 2026
Zim Laboratories Limited held its 42nd AGM on June 29, 2026. All four resolutions, including the adoption of FY26 financial statements and director re-appointment, were passed. The meeting concluded at 1:23 p.m. IST.
Read the summary - Low impact
Zim Laboratories Limited Holds 42nd AGM, Approves Key Resolutions
Zim Laboratories Limited held its 42nd Annual General Meeting on June 29, 2026. Key resolutions approved included the adoption of FY26 financial statements, re-appointment of a director, and ratification of cost auditor remuneration. All resolutions passed with overwhelming majority via e-voting.
Read the summary - Low impact
Zim Laboratories Limited Closes Trading Window from July 1, 2026
Zim Laboratories Limited is closing its trading window from July 1, 2026, for designated persons and their relatives. The window will reopen 48 hours after the company declares its financial results for the quarter ended June 30, 2026.
Read the summary - Low impact
Zim Laboratories to Meet Florintree Trinex LLP on June 19, 2026
Zim Laboratories Limited will conduct a one-to-one in-person meeting with Florintree Trinex LLP on June 19, 2026. The company has noted that the schedule is subject to change and no sensitive information will be disclosed.
Read the summary - Low impact
Zim Laboratories to hold Investor Meet on June 17, 2026
Zim Laboratories Limited has scheduled a virtual one-on-one investor and analyst meet for June 17, 2026. The company will provide updates as per SEBI regulations, ensuring no Unpublished Price Sensitive Information is disclosed.
Read the summary - Low impact
ZIM Labs Promoter Anwar Daud to Acquire 80,000 Shares from Zulfiquar Kamal
Dr. Anwar Daud, a promoter of Zim Laboratories Limited, will acquire 80,000 shares (0.15%) from fellow promoter Mr. Zulfiquar Kamal. The transaction is an off-market inter-se transfer, exempt under SEBI SAST Regulations. The acquisition can occur on or after June 11, 2026. Post-transaction, Dr. Daud's stake will be 25.05%.
Read the summary - Low impact
Zim Laboratories revises AGM date to June 29, 2026
Zim Laboratories Limited has revised the date for its 42nd Annual General Meeting (AGM). The AGM will now take place on Monday, June 29, 2026, at 11:30 a.m. IST via Video Conferencing. This change is due to unforeseen circumstances, with all other prior details remaining the same.
Read the summary - Low impact
Zim Laboratories Announces 42nd AGM on June 26, 2026, via VC/OAVM
Zim Laboratories Limited will hold its 42nd Annual General Meeting on June 26, 2026. The meeting will be conducted via Video Conferencing (VC) and Other Audio Visual Means (OAVM). Newspaper advertisements have been published to inform shareholders.
Read the summary - High impact
Zim Laboratories Releases Q4 & FY26 Earnings Call Transcript; EU GMP Inspection Outcome Expected Positively
Zim Laboratories released its Q4 & FY26 earnings call transcript. The company expects a positive outcome from its recent EU GMP re-inspection. FY26 revenue was stable at ₹374.4 crore, impacted by geopolitical issues in MENA. Q4 revenue was ₹105.3 crore. Significant investments were made in NIP and OTF platforms.
Read the summary - Low impact
Zim Laboratories Q4 & FY26 Earnings Conference Call Audio Recording Available
Zim Laboratories Limited has released the audio recording of its Q4 and FY26 Earnings Conference Call. The recording is accessible via a provided link on the company's website.
Read the summary - Low impact
Zim Laboratories Limited Publishes Financial Results for Q4FY26
Zim Laboratories Limited announced its Q4FY26 financial results. Consolidated total income was ₹1087.33 lakhs, with a net profit after tax of ₹188.45 lakhs for the quarter. For the full year, consolidated income reached ₹7808.10 lakhs, and net profit after tax was ₹1216.50 lakhs. The results were approved by the Board on May 19, 2026.
Read the summary - Medium impact
Zim Laboratories Files Q4 & FY26 Earnings Presentation
Zim Laboratories reported Q4 FY26 revenue of ₹1,053 million and FY26 revenue of ₹3,744 million. FY26 EBITDA was ₹414 million, with a margin of 11.1%. The company received approval for Dabigatran Etexilate in Italy in May 2026. An Advisory Board has been formed, and the company approved a preferential issue of shares aggregating ₹35 crore.
Read the summary - Medium impact
Zim Laboratories Gets Marketing Authorization for Dabigatran Etexilate in Italy
Zim Laboratories Limited's European subsidiary received Marketing Authorization from AIFA for Dabigatran Etexilate capsules in Italy. This approval is anticipated to accelerate market entry in other EU countries and globally. The EU market for this product was approximately USD 392.84 million in 2025.
Read the summary - Low impact
Zim Laboratories Appoints Dhananjay V. Joshi & Associates as Cost Auditor for FY 2026-27
Zim Laboratories appointed M/s Dhananjay V. Joshi & Associates as Cost Auditor for FY 2026-27 during its board meeting on May 19, 2026. The board meeting commenced at 12:45 p.m. (IST) and concluded at 4:30 p.m. (IST). The appointment follows Section 148 of the Companies Act, 2013 and SEBI regulations.
Read the summary - Medium impact
ZIMLAB Approves Audited FY26 Results, Appoints Cost Auditor
Zim Laboratories Limited's board approved the audited standalone and consolidated financial results for the year ended 31 March 2026 on 19 May 2026. Deloitte Haskins & Sells LLP issued an unmodified opinion on the results. M/s Dhananjay V. Joshi & Associates were appointed as Cost Auditor for FY27.
Read the summary - Low impact
Zim Laboratories Announces Q4 & FY26 Earnings Conference Call on 20 May 2026
Zim Laboratories will hold a Q4 & FY26 earnings conference call on May 20, 2026, at 12:00 p.m. IST. Key participants include Dr. Anwar Siraj Daud, Mr. Zulfiquar Kamal, Mr. Shyam Mohan Patro, and Mr. Zain Daud. The call is hosted by Go India Advisors. Participants can pre-register or dial in using the provided numbers.
Read the summary - Medium impact
Zim Laboratories Completes EU GMP Inspection by German & Portuguese Authorities
Zim Laboratories Limited's manufacturing facility in Kalmeshwar, Nagpur, has successfully completed an EU GMP inspection conducted by German and Portuguese regulatory authorities. The inspection took place from May 4 to May 7, 2026. The company reaffirmed its commitment to quality and regulatory compliance.
Read the summary - Low impact
Zim Laboratories Promoter Zulfiqar Kamal Reports No Share Encumbrance for FY26
Zim Laboratories Promoter Zulfiqar Kamal and Persons Acting in Concert reported no encumbrance of shares for the Financial Year ended March 31, 2026. This disclosure was made on April 1, 2026, in compliance with SEBI Takeover Regulations.
Read the summary - Low impact
Zim Laboratories Promoter Reports No Share Encumbrance for FY26
Anwar Siraj Daud, Promoter of Zim Laboratories Limited, declared no share encumbrance for the financial year ended March 31, 2026, as per SEBI Takeover Regulations. This disclosure was made to both BSE and NSE.
Read the summary - Medium impact
Zim Laboratories Invests ₹89.45 Lakhs in ZIMTAS Pty Ltd, Acquires 99.96% Stake
Zim Laboratories Limited invested ₹89.45 Lakhs (AUD 1.35 Lakhs) in ZIMTAS Pty Ltd, acquiring a 99.96% stake. This is part of an approved investment of up to ₹2.00 Crores.
Read the summary - Low impact
Zim Laboratories Limited Files SEBI Regulation 74(5) Certificate for Q4 FY26
Zim Laboratories Limited has filed a certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The company's RTA, MUFG Intime India Private Limited, confirmed the processing of dematerialized securities and cancellation of physical certificates.
Read the summary - Low impact
Zim Laboratories Appoints Grant Thornton Bharat LLP as Internal Auditors for 3 Years
Zim Laboratories Limited has appointed Grant Thornton Bharat LLP as its Internal Auditors for a three-year term from FY 2026-27 to FY 2028-29. The Board of Directors approved this appointment on March 30, 2026. Grant Thornton is a prominent professional services firm.
Read the summary - Low impact
Zim Laboratories Limited Closes Trading Window from April 1, 2026
Zim Laboratories Limited will close its trading window from April 1, 2026. The window will reopen 48 hours after the declaration of financial results for the quarter and year ended March 31, 2026.
Read the summary - Medium impact
ZIM Laboratories Constitutes Advisory Board for Strategic Guidance
Zim Laboratories formed an Advisory Board on March 17, 2026, including Mr. Annaswamy Vaidheesh (Chairman), Mr. Gautam Saigal, and Mr. Girdhar Balwani as members. The board will provide strategic guidance on business development, market expansion, and organizational structure.
Read the summary - Low impact
Zim Laboratories to hold Investor Meet on March 20, 2026
Zim Laboratories Limited will hold a virtual one-to-one investor meet with Everflow Partners on March 20, 2026. The company will not share any Unpublished Price Sensitive Information during the meeting.
Read the summary - Medium impact
Zim Laboratories Allots 47.64 Lakh Equity Shares Worth ₹35 Cr via Preferential Issue
Zim Laboratories approved the allotment of 47,64,497 equity shares via preferential issue for ₹34.99 crore. The issue price was ₹73.46 per share. Florintree Trinex LLP is the sole investor. This raises the company's paid-up capital to ₹53.50 crore.
Read the summary - Low impact
Zim Laboratories Middle East DMCC closure approved by DMCC Authority effective Feb 23, 2026
Zim Laboratories Middle East DMCC, a step-down subsidiary of Zim Laboratories Limited, will be officially closed. The Dubai Multi Commodities Centre Authority has approved the dissolution, effective February 23, 2026. This action was previously approved by the company's Board of Directors on August 7, 2025.
Read the summary - Low impact
Zim Laboratories Limited's Credit Ratings Reaffirmed by ACUITE Ratings
ACUITE Ratings & Research Limited has reaffirmed Zim Laboratories Limited's credit ratings. Long-term facilities of ₹150.23 crore received an 'ACUITE BBB | Stable' rating, and short-term facilities of ₹16.00 crore were reaffirmed as 'ACUITE A3+'. The announcement was made on February 17, 2026.
Read the summary - Medium impact
Zim Laboratories Limited Q3 & 9MFY26 Earnings Call Transcript Released
Zim Laboratories Limited released its Q3 & 9MFY26 earnings call transcript. The company is progressing with EU-GMP remediation, expecting an audit in H1FY27. A preferential issue of ₹35 crore was completed for facility expansion and compliance. Key leadership appointments were made. Q3 FY26 saw operating income of ₹108.7 crore and EBITDA of ₹14.5 crore.
Read the summary - Medium impact
Zim Laboratories Limited Holds EGM; Approves Preferential Issue of Equity Shares
Zim Laboratories Limited held an EGM on February 16, 2026, to approve a preferential issue of equity shares. The special resolution passed with 99.9896% of votes in favor. The meeting was attended by 6 promoters and 36 public shareholders via video conference.
Read the summary - Low impact
Zim Laboratories Limited Holds 1st EGM for FY25-26 on Feb 16, 2026
Zim Laboratories Limited held its 1st EGM for FY25-26 on February 16, 2026, via video conference. The meeting focused on a proposed preferential issue of equity shares. Key management and auditors were present. The EGM commenced at 11:30 AM and concluded at 12:19 PM.
Read the summary - Low impact
Zim Laboratories Releases Q3 & 9M FY26 Earnings Conference Call Audio Recording
Zim Laboratories Limited has released the audio recording of its Q3 and 9M FY26 Earnings Conference Call. The recording is available on the company's website. This update complies with SEBI Listing Regulations.
Read the summary - Low impact
Zim Laboratories Announces Newspaper Publication for Q3 FY26 Financial Results
Zim Laboratories Limited announced the publication of its financial results for the quarter and nine months ended December 31, 2025. The disclosure was made on February 12, 2026, in the Financial Express, Indian Express, and Loksatta newspapers, in compliance with SEBI regulations.
Read the summary - Medium impact
Zim Laboratories Approves Q3 FY26 Results and Chilean Subsidiary Investment
Zim Laboratories Limited reported its unaudited financial results for the quarter and nine months ended December 31, 2025. The company also approved an investment of up to USD 15,000 to establish a wholly-owned subsidiary in Chile, aiming for expansion in the LATAM region.
Read the summary - Medium impact
Zim Laboratories Receives GST Demand Notice of ₹2.20 Crore
Zim Laboratories Limited received a GST Demand Notice dated December 30, 2025, for FY 2021-22. The notice from the Deputy Commissioner of State Tax, Nagpur, aggregates to ₹2.20 crore, including GST, interest, and penalty. The company is assessing the demand and plans to file an appeal, anticipating no material financial impact.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio